secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001558370-25-011218
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q2 net loss $0.19/sh; Phase 1b PD study fully enrolled, data by Q4 2025
--------------------------------------------------------------------------------

- Phase 1b of GT-02287 in Parkinson's reached target enrollment in Q2 2025 with 16 patients; up to 20 total.
- Functional and biomarker analysis from 90-day dosing expected in Q4 2025; extension request submitted.
- Net loss per share $0.19 vs $0.42 YoY; R&D spend down to $2.8M on grant income and credit.
- Cash $6.7M as of June 30; July 2025 public offering raised ~$7.1M net, extending runway past Phase 1b.
- IND submission to FDA for GT-02287 expected by year-end 2025 to enable US Phase 2 expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/0001558370-25-011218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/ganx-20250812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer